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Allergic Rhinitis: Agency for Healthcare Research
and Quality or Anchor-Based Thresholds?Eli O. Meltzer, MDa,b, Dana Wallace, MDc, Mark Dykewicz, MDd, and Lucy Shneyer, MAe San Diego, Calif; Fort
Lauderdale, Fla; St. Louis, Mo; and Denville, NJWhat is already known about this topic? Multiple approaches have been suggested for estimating a minimal clinically
important difference (MCID) for allergic rhinitis studies, with most based on the total nasal symptom score (TNSS). Most
recently, in 2013, the Agency for Healthcare Research and Quality (AHRQ) in the USA recommended using an MCID
equal to 30% of the maximum TNSS as a useful threshold. Treatment differences that failed this threshold would indicate
equivalence. However, evaluations testing this threshold by the AHRQ and subsequent investigators could not demon-
strate differences in effectiveness between various treatments for seasonal allergic rhinitis.
What does this article add to our knowledge? This article describes the use of a threshold determined using a validated
anchor-based approach that can be applied to allergic rhinitis clinical studies with appropriate data. By applying this
threshold to 3 of the queries in the AHRQ report, using that same database, the article demonstrates the differences in
outcomes. MCIDs for patient symptom relief were attainable for the majority of studies, despite the negative results re-
ported by the AHRQ. In contrast to the results of the AHRQ analysis, the outcomes shown in this article are those that
would be expected based on other reports in the published literature, including current management guidelines.
How does this study impact current management guidelines? The MCID calculations using the validated anchor-
based estimate reported here support most of the recommendations of current management guidelines. The ﬁnding that
intranasal corticosteroid with intranasal antihistamine in the same device was more effective than either monotherapy
alone should be carefully reviewed for future guidance documents. In addition, we believe that the approach used in this
article currently represents the only reasonable method to determine an MCID for allergic rhinitis studies and should
supersede the method and consequent ﬁndings of the AHRQ report.BACKGROUND: In 2013, the Agency for Healthcare Research
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AHRQ- Agency for Healthcare Research and QualityAR- Allergic rhinitis
AZE- Azelastine
BDP- Beclomethasone dipropionate
BL- Baseline
DB- Double blind
DD-Double dummy
FP- Fluticasone propionateGRCS- Global rating of change score
INAH- Intranasal antihistamine
INCS- Intranasal corticosteroid
LOR- Loratadine
LTRA- Leukotriene receptor antagonist
MC-MulticenterMCID-Minimal clinically important difference
MeSH-Medical subject heading
MON-Montelukast
MOM-Mometasone furoate nasal spray
mm-MillimeterMP-AzeFlu- Azelastineþﬂuticasone propionate in a single device
OAH- Oral antihistamine
OLO- OlopatadineP- Placebo
PC- Placebo controlled
PG- Parallel group
PM- Evening
QD-Once daily
R- RandomizedSAR- Seasonal allergic rhinitis
SD- Standard deviationSLIT- Sublingual allergen immunotherapy
Sx- SymptomsTNSS- Total nasal symptom score (r, reﬂective)
TSS4- Total symptom score 4 (another descriptor for TNSS)Tx- Treatment
VAS- Visual analog scaleAR studies, with an absolute value for an anchor-based
threshold and validated methods for calculating distribution-
based thresholds.
METHODS: Using the same studies as the AHRQ report,
anchor- and distribution-based MCID thresholds were deter-
mined for 3 clinical comparisons identiﬁed by the AHRQ:
(1) oral antihistamineDintranasal corticosteroid (INCS) versus
INCS, (2) montelukast versus INCS, and (3) intranasal anti-
histamineDINCS in a single device versus the monotherapies.
The outcomes were compared with those reported using the
AHRQ threshold.
RESULTS: No treatment comparison met the AHRQ-deﬁned
MCID threshold; all treatments were determined to be equivalent
for all 3 queries. In contrast, the evidence-based model revealed
some differences between treatments: INCS > montelukast; intra-
nasal antihistamineDINCS > either monotherapy. No clinically
relevant beneﬁt was observed for adding an oral antihistamine to
INCS, but some studies were not optimal choices for quantitative
determination of MCIDs. Updating the literature search revealed
no additional studies that met the AHRQ inclusion criteria.
CONCLUSIONS: The evidence-based threshold for MCID
determination for AR studies should supersede the threshold rec-
ommended in the AHRQreport.  2016The Authors. Published
by Elsevier Inc. on behalf of the American Academy of Allergy,Asthma& Immunology. This is an open access article under theCC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/). (J Allergy Clin Immunol Pract 2016;4:682-8)
Key words: Allergic rhinitis; Oral antihistamine; Intranasal
antihistamine; Intranasal corticosteroid; Leukotriene receptor
antagonist; Minimal clinically important difference (MCID);
Seasonal allergic rhinitis (SAR); Total nasal symptom score
(TNSS)
Evidence-based medicine integrates research outcomes, clinical
expertise, and patient expectations to optimize clinical decision
making during treatment. A key pillar of the evidence-based
approach is the concept that, to be considered effective, a therapy
shouldprovide both statistically signiﬁcant and clinicallymeaningful
differences over a placebo and/or active comparators. What is clin-
ically meaningful can be estimated through determination of a
minimal clinically important difference (MCID),which is deﬁned as
the minimal amount of a treatment effect (or change) that is
important to the patient.1-4 How to measure this in a manner that
incorporates the patient’s perspective yet allows for appropriate
comparison of different treatments is subject to discourse.
Multiple evidence-based methods for determining an MCID
have been described, with most falling into 2 classes: anchor-
based and distribution-based approaches. Both can be used to
determine the magnitude of a clinically relevant treatment effect
size from a population perspective that is, quantitatively, based
on treatment group means.1,2,5
As named, the anchor-based approach links a change in a desired
outcome measure to a “meaningful” external anchor that reﬂects the
patient’s perspective, such as the global rating of change score
(GRCS) bywhich patients rate their impression of treatment.1,2,6 For
example, the patient might be asked to ﬁnish the statement, “Since
starting therapy my symptoms are,” using an ordinal scale from7
(very much worse) to 0 (no change) to þ7 (very much better).
Distribution-based approaches assess statistically signiﬁcant
changes in the desired outcome measure in relation to the
probability of change occurring by chance. For example, a clin-
ically meaningful effect might be deﬁned as a change above an
arbitrary multiple of the sample standard deviation (SD) for the
measure at baseline.1,2,6 Because distribution-based methods are
sample speciﬁc, MCID scores can be determined by statistical
analysis alone, even when a change from baseline is difﬁcult to
detect (eg, in studies with large sample sizes and variances).2
However, unlike anchor-based approaches, distribution-based
calculations are not necessarily linked to any patient perspec-
tive of a clinically meaningful response. Consequently, anchor-
based MCIDs are generally considered more robust.1,2,7,8
Determining an MCID in allergic rhinitis studies
How MCID comparisons apply to clinical decision making
varies by disease state.1,2,7 For some, including allergic rhinitis
(AR), how to calculate the MCID remains a point of discussion.
To date few articles have addressed this issue for AR, and those
that have—including guidances from government health care
agencies in the European Union and the United States—suggest
widely different approaches (see Appendix E1 available in this
article’s Online Repository at www.jaci-inpractice.org).1,8-12
For the patient, AR is a disease characterized by annoying
symptoms, and, reﬂecting this, the most commonly used scale to
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which is typically the sum of the individual symptom scores for
nasal itching, rhinorrhea, sneezing, and nasal congestion.9,13 In
most clinical trials, each of these symptoms is rated on a scale
from 0 to 3 (0 ¼ none, 1 ¼ mild, 2 ¼ moderate, 3 ¼ severe)
twice daily. Both morning þ evening (AMþPM) sums and
averages have been reported in the literature, so the TNSS can
range from 0 to 12 or 0 to 24 according to the study design. Less
frequently, the TNSS may be rated on a 0- to 4-point scale or, in
some studies, symptoms may be rated on a visual analog scale
(VAS) from 0 to 100 mm, resulting in a TNSS range of 0-400
mm. Nonetheless, the TNSS is the most accepted primary efﬁ-
cacy variable that is rated for drug approval in AR in the USA,13
so, when considering clinical relevance, it is appropriate to assess
MCID in relation to the TNSS.
The different methods proposed for determining MCIDs in
AR studies (Appendix E1, available in this article’s Online
Repository at www.jaci-inpractice.org) underscore the need to
better understand how to evaluate what is a meaningful change
to the patient in a manner that is both evidence based and able to
compare treatment means. A recent attempt to do this was
published by the Agency for Healthcare Research and Quality
(AHRQ) in the USA in 2013. The agency sought to develop an
approach for determining an MCID threshold to evaluate drug
classes used to treat seasonal AR (SAR), including oral and nasal
antihistamines and decongestants; intranasal corticosteroids
(INCS); the mast cell stabilizer, intranasal cromolyn sodium; the
anticholinergic, intranasal ipratropium; the oral leukotriene
receptor antagonist (LTRA), montelukast; and nasal saline.8 The
evaluation was conducted by a panel convened by the Blue Cross
and Blue Shield Association Technology Evaluation Center,
using the TNSS as the measure of effectiveness based on meta-
analyses of studies evaluating single treatments and combina-
tions of treatments.8 According to that panel, “anchor-based
MCIDs have not been deﬁned for rhinitis symptom scales.”
Thus, a subpanel of 3 recommended post hoc an MCID equal to
30% of the maximum TNSS (eg, 3.6 points on a 12-point
scale) as a useful threshold. Treatment differences that failed
this threshold would indicate equivalence. The panel acknowl-
edged that validation of this deﬁnition of MCID using an
anchor-based approach would be desirable.
Applying this threshold, the AHRQpanel could not demonstrate
any differences in effectiveness between the various therapeutic
classes, which they mostly attributed to insufﬁcient evidence to
support the superiority of one treatment over another.8 Although
the lack of good comparative data for some of the comparisons
certainly contributed to the outcomes, of greater concern is that the
AHRQ method was ﬂawed in 2 important ways.
The ﬁrst arises from using the maximum possible score of a
bounded outcome to determine the threshold. This method
creates problems around the lower bound. In the case of the
AHRQ threshold, using the ﬁxed number of 3.6 points (on a
12-point scale) based on 30% of the maximum TNSS could
ultimately negate milder levels of AR from being clinically rele-
vant. Speciﬁcally, any study population with an average baseline
score of 3.5 or less could not attain the MCID threshold of 3.6,
even when treatment eliminated all symptoms in every patient
(ie, posttreatment value ¼ 0).
Second, although the 30% criterion could be relevant for an in-
dividual patient response, there was no indication of how it could be
applied to a comparison of differences in population means.Applying the panel members’ opinion of patient response to
population-based differences in treatment means from clinical trials
resulted in overestimation of the MCID threshold, which can be
demonstrated by comparing the conclusions based on the applica-
tion of theAHRQthreshold directly with those based on a threshold
derived from an earlier publishedmethod authored by Barnes et al.1
Barnes et al1 developed and tested anchor- and distribution-
based models to determine MCID thresholds for AR treat-
ments, using pooled data from 9 randomized, placebo-controlled
studies (n ¼ 204 subjects with mild-to-moderate AR). These
evidence-based models provide clinicians with an absolute value
for an anchor-based threshold and validated methods for calcu-
lating distribution-based thresholds.1
The anchor-basedMCID threshold value for a TNSS scale of 0-
12 points was 0.23 or 0.28 points depending onwhether regression
or meta-analytical methods, respectively, were applied, and was
derived from calculations establishing a relationship between
GRCS (as a direct anchor) and TNSS.1 For a TNSS scale of 0-24
points, the comparableMCID thresholdswould be 0.46 points (by
regression analysis) or 0.56 points (bymeta-analysis), and for a 400
mm VAS, the upper threshold was 9.33 mm.
The distribution-based model applied commonly used statis-
tical methods for determining effect size by measuring the dis-
tance between 2 treatment means in relation to the baseline SD
of the sample (eg, Hedge’s g, Cohen’s d).1 Validity analyses for all
the methods tested were described in detail. For more informa-
tion about the calculations, the reader is referred to Appendix E2,
available in this article’s Online Repository at www.jaci-
inpractice.org.
Brixner et al5 applied the higher, more conservative anchor-
based threshold of 0.28 points1 to TNSS data reported in the
approved prescribing information for intranasal azelastine
hydrochloride (AZE), ciclesonide, ﬂuticasone furoate, and the
combination of azelastine and ﬂuticasone propionate (FP) in a
single device (MP-AzeFlu), and then compared those MCID
outcomes with the 30% threshold recommended by the AHRQ
panel.8 All 4 products achieved the threshold of a “clinically
meaningful” change compared with placebo using the anchor-
based estimate; in contrast, none showed any clinical beneﬁt
over placebo based on the AHRQ 30% threshold.5 These
observations suggest that applying the Barnes models to the
dataset used in the AHRQ report would yield different results
and would support the Barnes et al1 recommendations for how
to best determine an MCID in AR studies.METHODS
In a new series of assessments, anchor- and distribution-based
MCID thresholds using the estimates and methods described by
Barnes et al1 were compared with the AHRQ report (2013)8 rec-
ommended threshold of 30% of the TNSS maximum for
3 treatment-related clinical questions evaluated in the AHRQ report:
1. Is there any clinical beneﬁt to adding an oral antihistamine
(OAH) to an INCS?
2. How does the LTRA, montelukast, compare with INCSs in
terms of clinical beneﬁt?
3. Is there any clinical beneﬁt to adding an intranasal antihistamine
(INAH) to an INCS in a single device?
The questions were chosen based on outcomes in the AHRQ
report suggesting that the treatments were equivalent in terms of
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ﬁndings that are in opposition to other published data,14-26
including national and international guideline recommendations,
and to the clinical experience of the authors of this article.
The clinical studies described in the AHRQ report provided the
initial dataset for analysis. The inclusion criteria were studies of SAR,
at least 2 weeks in duration. All subjects had a minimum of a 2-year
clinical history of SAR of mild-to-moderate severity, with positive
skin prick test results in the year before study, but otherwise were in
good health.
Studies published subsequent to the AHRQ report8 were
searched using a similar strategy to that described by the AHRQ
panel: MEDLINE, Embase, and the Cochrane Library were
searched for articles in English reported between July 18, 2012, and
September 8, 2015. Only search terms relevant to the 3 queries were
used, and as described in the AHRQ report,8 head-to-head ran-
domized controlled trials were preferred for analysis, but also
included were nonrandomized trials and comparative observational
studies that were blinded and controlled for confounders. The spe-
ciﬁc search strategy is described in Appendix E3 (available in this
article’s Online Repository at www.jaci-inpractice.org).
For each study in the dataset, the absolute change in the TNSS
from baseline by treatment was calculated and evaluated according to
the different thresholds, with speciﬁc between-treatment compari-
sons assessed by query. For the anchor-based approach, the Barnes
anchor-based MCID threshold of 0.28 points for a TNSS scale of
0-12 points was applied (0.56 points for a scale of 0-24; 9.33
mm for a 400 mm VAS).1 For the AHRQ recommendation, the
threshold of 3.6 points on a TNSS scale of 0-12 scale was used
(7.2 points for a scale of 0-24; 120 mm on a 400 mm VAS).8
A distribution-based calculation using Hedge’s g (or Cohen’s d)
was performed to further assess the results of the threshold ﬁndings.
The calculation, which is study speciﬁc and is based on both the
difference in treatment means and the weighted average baseline SD,
is described in full in Appendix E2 (available in this article’s Online
Repository at www.jaci-inpractice.org). The MCID threshold for
Hedge’s g (or Cohen’s d) is 0.2.
RESULTS
Only studies from the AHRQ report8 (2013) were used in the
dataset; the extended search found no additional studies meeting
the AHRQ criteria for inclusion.12,22,23,27,28-36 The studies are
described in Appendix E4 (available in this article’s Online
Repository at www.jaci-inpractice.org).
Tables I-III summarize the MCID outcomes for the different
approaches by query. Overall, none of the treatment comparisons
in the studies assessed in the AHRQ met the 30% threshold
recommended by their panel to deﬁne a minimal clinically
important difference between treatments. Thus, all treatments
were determined to be equivalent for each of the 3 queries.
When using the anchor-based threshold or the respective
Hedge’s g, some queries showed results greater than the MCID
whereas others did not. Each query is summarized below.
Query 1: Is there any clinical benefit to adding an
OAH to an INCS?
Three clinical trials compared concurrent use of oral selective
antihistamine plus INCS with INCS monotherapy (Table I):
2 looking at the addition of loratadine to either mometasone
furoate28 or FP29 and 1 evaluating the addition of levocetirizine
to FP.12 The outcomes of all 3 showed little or no clinicallyrelevant superiority for the combination, regardless of how
MCID was calculated. Two studies did not reach the anchor-
based threshold of a 0.28-point difference between treatment
groups in the TNSS change from baseline,12,29 and the third was
borderline and could not be conﬁrmed by distribution-based
methods because of a lack of precision in reported data.28
However, none of the selected studies were optimal choices for
quantitative determination of MCIDs.
Query 2: How does montelukast compare with an
INCS in terms of clinical benefit?
Five trials compared montelukast with an INCS (Table II);
4 had sufﬁcient data with which to assess clinical beneﬁt by at
least 1 method: 1 using beclomethasone dipropionate30 and the
others FP.31-34 Although none reached the AHRQ threshold, all
showed clinically relevant between-treatment differences at
2 weeks using the anchor-based approach, favoring the INCS
over montelukast. In addition, for 3 of the 4 studies,31-33 the
anchor-based data were supported by distribution-based calcu-
lations (Hedge’s g) demonstrating effect sizes exceeding the
MCID threshold of 0.2 points. Distribution-based calculations
could not be applied to the other 2 studies,30,34 as described in
Table II.
Query 3: Is there any clinical benefit to adding an
INAH to an INCS in a single device?
Four studies compared the combination of an INCS and
INAH (FP, AZE) with the individual monotherapies
(Table III).22,23,27,35 Although none reached the AHRQ
threshold, all 4 studies achieved the effect size for the anchor-
based MCID threshold showing superiority of MP-AzeFlu over
either monotherapy. The anchor-based results were supported by
distribution-based calculations also demonstrating MCID supe-
riority for MP-AzeFlu over either AZE or FP alone. (See
Appendix E2, available in this article’s Online Repository at
www.jaci-inpractice.org, for a description of the speciﬁc
calculations.)
DISCUSSION
To date, there is one published report describing validated
evidence-based methods for determining an MCID in AR
studies, including both anchor-based and distribution-based
approaches—the paper authored by Barnes et al1 published in
2010. Their anchor-based thresholds can be directly applied to
AR clinical studies with appropriate data, and the relatively
simple distribution-based calculation (see Appendix E2 available
in this article’s Online Repository at www.jaci-inpractice.org) can
be used to support borderline anchor-based outcomes.
Application of these methods and thresholds to 3 of the same
queries evaluated in the AHRQ report and using their database
yielded different outcomes from those reported by the AHRQ
panel.8 Speciﬁcally, in terms of reaching an MCID for patient
symptom relief, we found that (1) OAH þ INCS w INCS,
(2) INCS > montelukast, and (3) MP-AzeFlu or AZEþFP >
AZE or FP. These are outcomes that would be expected from
other reviews and meta-analyses in the literature and from phy-
sicians’ clinical experience.16-20,22-26 As such, the methods and
estimates reported by Barnes et al1 are recommended to deter-
mine an MCID in AR studies.
At this time, other than the approach described in the Barnes
paper,1 there are no other appropriate and validated methods to
TABLE II. Query 2: How does montelukast compare with an intranasal corticosteroid in terms of clinical benefit?
Study Tx
Difference between
Tx in TNSS change
from BL @ 2 wk* Hedge’s g*
MCID threshold met?
CommentsAHRQ†
Anchor
basedz
Distribution
basedx
Lu et al, 200930 Study 1: BDP
vs MON
0.34 NA No Yes NA Although assay sensitivity can be
conﬁrmed by Tx differences for
monotherapy arms, the data
reported were the average of
AMþPM TNSS (0-3) without BL
SDs—so cannot determine
Hedge’s g
Martin et al,
200631
FP vs MON 33.6jj 0.63 No Yes Yes DT TNSS reported only
Nathan et al,
200532
FP vs MON 26.1jj 0.33 No Yes Yes Subjects all had asthma and used
concomitant inhaled FP and/or
salmeterol combination
DT TNSS reported only
Ratner et al,
200333
FP vs MON 36.3{ 0.72 No Yes Yes DT TNSS reported only
Pullerits et al,
200234
FP vs MON NA NA NA NA NA Inappropriate due to size (<20
subjects), incomplete results, and
design (prophylaxis, ie, Sx stability
rather than improvement)
AHRQ, Agency for Healthcare Research and Quality; AM, morning; BDP, beclomethasone dipropionate; BL, baseline; DT, daytime; FP, ﬂuticasone propionate; MCID, minimal
clinically important difference; MON, montelukast; PM, evening; SD, standard deviation; Sx, symptom(s); TNSS, total nasal symptoms score; Tx, treatment; VAS, visual analog
scale.
*Change (greater (þ) or less ()) in reduction in symptoms of ﬁrst drug/drug combination when compared with second drug/drug combination and third drug/drug combination.
†AHRQ panel threshold: 30% difference in maximum TNSS change from BL (ie, 3.6 on a 0-12 scale, 7.2 on a 0-24 scale, or 120 mm on a 400 mm VAS).8
zAnchor-based estimate: 0.28 for a scale of 0-12, 0.56 for a scale of 0-24 (indicated by {), and 9.33 mm for a 400 mm VAS (indicated by jj).1
xDistribution-based threshold: magnitude of Hedge’s g 0.20 SD (see the text and Appendix E1, available in this article’s Online Repository at www.jaci-inpractice.org).
TABLE I. Query 1: Is there any clinical benefit for adding an oral antihistamine to an intranasal corticosteroid (INCS)?
Study Tx
Difference
between Tx in
TNSS change from
BL @ 2 wk* Hedge’s g*
MCID threshold met?
CommentsAHRQ†
Anchor
basedz
Distribution
basedx
Anolik et al,
200828
MOMþLOR
vs MOM
0.3 0.13 No Yes No Reported data lack precision; assay
sensitivity is conﬁrmed by Tx
differences for monotherapy arms
vs P
Barnes et al,
200612
FPþLCET vs
FPþP
0.11 NA No No N/A Crossover design with single BL SD,
so cannot determine Hedge’s g; but
Cohen’s d ¼ 0.043, not meeting
the distribution-based MCID
threshold, 0.20
Lack of controls limits interpretation
of clinical relevance and assay
sensitivity
Ratner et al,
199829
FPþLOR vs
FP
þ1.0jj þ0.02 No No No Tx difference for INCS monotherapy
conﬁrmed assay sensitivity.
Physician-evaluated Sx scores
AHRQ, Agency for Healthcare Research and Quality; BL, baseline; FP, ﬂuticasone propionate; MCID, minimal clinically important difference; LCET, levocetirizine; LOR,
loratadine; MOM, mometasone furoate nasal spray; P, placebo; Sx, symptom(s); TNSS, total nasal symptoms score; Tx, treatment; VAS, visual analog scale.
*Change (greater (þ) or less ()) in reduction in symptoms of ﬁrst drug/drug combination when compared with second drug/drug combination and third drug/drug combination.
†AHRQ panel threshold: 30% difference in maximum TNSS change from BL (ie, 3.6 on a 0-12 scale, 7.2 on a 0-24 scale, or 120 mm on a 400 mm VAS).8
zAnchor-based estimate: 0.28 for a scale of 0-12, 0.56 for a scale of 0-24 (indicated by jj) and 9.33 mm for a 400 mm VAS.1
xDistribution-based threshold: magnitude of Hedge’s g  0.20 SD (see the text and Appendix E1, available in this article’s Online Repository at www.jaci-inpractice.org).
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AHRQ method could not detect differences between classes of
drugs,8 nor is it even sensitive enough to detect differencesbetween products with demonstrated activity and placebo con-
trols in a later assessment.5 Other alternative methods have been
considered, but they all lack validation. One approach using
TABLE III. Query 3: Is there any clinical benefit to adding an intranasal antihistamine to an intranasal corticosteroid (INCS) in a single
device?
Study Tx
Difference between
Tx in TNSS change
from BL @ 2 wk* Hedge’s g*
MCID threshold met?
CommentsAHRQ†
Anchor
basedz
Distribution
basedx
Hampel et al, 201035;
Meltzer et al, 201322
MP29-02, aka
MP-AzeFlu vs
FP
AZE
1.47jj
2.06jj
0.45
0.61
No
No
Yes
Yes
Yes
Yes
Carr et al, 2012
Study MP400427
MP29-02, aka
MP-AzeFlu vs
FP
AZE
1.0jj
1.0jj
0.32
0.31
No
No
Yes
Yes
Yes
Yes
Carr et al, 2012
Study MP-400623
MP29-02, aka
MP-AzeFlu vs
FP
AZE
0.6jj
0.7jj
0.25
0.29
No
No
Yes
Yes
Yes
Yes
Carr et al, 2012
Study MP-400223
MP29-02, aka
MP-AzeFlu vs
FP
AZE
0.9jj
1.4jj
0.29
0.43
No
No
Yes
Yes
Yes
Yes
AHRQ, Agency for Healthcare Research and Quality; AZE, azelastine; BL, baseline; FP, ﬂuticasone propionate; MCID, minimal clinically important difference; SD, standard
deviation; SE, standard error; TNSS, total nasal symptoms score; Tx, treatment. VAS, visual analog scale.
*Change (greater (þ) or less ()) in reduction in symptoms of ﬁrst drug/drug combination when compared with second drug/drug combination and third drug/drug combination.
†AHRQ panel threshold: 30% difference in maximum TNSS change from BL (ie, 3.6 on a 0-12 scale, 7.2 on a 0-24 scale, or 120 mm on a 400 mm VAS).8
zAnchor-based estimate: 0.28 for a scale of 0-12, 0.56 for a scale of 0-24 (indicated by jj), and 9.33 mm for a 400 mm VAS.1
xDistribution-based threshold: magnitude of Hedge’s g  0.20 SD (see the text and Appendix E1, available in this article’s Online Repository at www.jaci-inpractice.org).
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50% or more reduction in a symptom score may, for individual
studies, add a measure of clinical relevance to statistically sig-
niﬁcant improvements in symptom scores.9,22,23 However,
responder analysis has not yet been broadly applied, and would
require validation to be used as a stand-alone global effect
measure. The World Allergy Organization recommended using a
relative clinical impact score, which evaluates the clinical effect of
an active treatment relative to the effect of a matched pla-
cebo.10,36 Although this has been used to determine clinical
beneﬁt for a meta-analysis of sublingual allergen immunotherapy
(SLIT) and pharmacotherapy in SAR,36 it is an indirect method
that needs validation. Comparable baseline scores are necessary
for between-treatment comparisons, and paradoxical effects may
arise when comparing prophylactic treatments such as SLIT with
in-season pharmacotherapy as well as from studies of intranasal
medications in which the intranasal placebos could, depending
on the amount of ﬂuid volume, possibly act as a nasal rinse.
These considerations serve to underscore the fact that, for now,
the Barnes approach is the only reasonable method to determine
an MCID for AR studies.
Further evaluation of the Barnes approach is needed—
particularly in terms of expanding its application. Questions
remain as to whether the methods could be applied to longer
term studies of perennial AR and chronic non-AR as well as to
other types of studies such as prophylaxis, with treatment started
before a pollen season. Application of the approach to risk of
harm analyses is another topic for further investigation. In
addition, the use of a 95% conﬁdence interval that includes
negative numbers calls into question how the conﬁdence interval
was determined. This needs to be addressed.
Given the limited number of clinical studies directly
comparing different classes of treatment, thought should also begiven to a fuller systematic review of the literature using ran-
domized, placebo-controlled studies with similar subject char-
acteristics at baseline. This would allow comparison of single
treatments and/or drug classes between studies as opposed to
within studies and may provide a broader database for
evaluation.15 At this time, evaluating the achievement of MCID
thresholds across studies is not always indicated because of dif-
ferences in trial designs and statistical data. For example, for
query 3, the AHRQ panel included a single study comparing use
of INAH þ INCS administered consecutively37 in addition to
the studies in which they were given in a single device.22,23,27,35
Although the separate administration showed similar trends in
MCIDs for adding the INAH to the INCS, the double-dummy
design and higher dose of the INAH used as well as the doubling
of spray volume into the nose negate a valid conclusion and
comparison to the studies using a single device. Hence, it is
important to verify that study designs are suited for a ﬁnal
quantitative assessment of the available products.
Maximizing the beneﬁt to the patient is a comprehensive goal
that requires a combination of symptom improvement, disease
control, and minimal risk of harm. In terms of clinical studies, a
means to link these outcomes to a measure of patient beneﬁt will
help clinicians, patients, and payers optimize the treatment
decision process. As a starting point, an MCID can be calculated
for many studies in AR, using validated anchor- and distribution-
based methods, thereby permitting some assessment of these
issues.1 Application of these methods discounts the ﬁndings of
the AHRQ report,8 while supporting the outcomes of earlier
systematic reviews comparing medication classes for AR.16-20
In conclusion, our recommendation is that the method of
Barnes et al1 for determining an MCID for AR studies and the
conclusions based on that method should supersede the method
and consequent ﬁndings of the AHRQ report.8
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MELTZER ETAL 688.e1ONLINE REPOSITORYAPPENDIX E1. Some proposed methods for determining MCID thresholds for allergic rhinitis (AR) treatments
Method How used and/or developed Rating Comments
An appropriate global effect
measure for AR?
EU/CHMP
Guideline
(2004)E1
Suggested in guidance as a
means to evaluate clinical
beneﬁt of medicinal
products for allergic
rhinoconjunctivitis
Responder analyses
based on the
proportion of
patients with 50%
reduction in a Sx
score
A change in score 3 has
generally been considered as a
clinically relevant
improvement of Sx based on
reductions from BL in rTSS4
or TNSS of 20%-35% for P
and 40%-50% for active Tx
Limitations:
 Not broadly tested, requires
validation with application to
meta-analyses
 How the difference in % re-
ductions relates to a score of 3
depends on the rating scale and
the magnitude of the BL scores
 Cannot compute without full
access to database
No, requires access to database(s)
for studies, and has other
limitations notedE1
WAO relative
clinical
impactE2,E3
Applied to immunotherapy Relates differences in
active Tx effects to
placebo score
Appropriate for systemic
prophylaxis when Tx is
initiated before allergy season
and BL severity is not
considered
Limitations:
 BL severity must be equal or
close to 0 for cross-study
comparisons
 Intranasal spray placebos might
be considered to have some
activity as nasal washes, and
would not be appropriate for
comparisons to oral or subcu-
taneous Tx
 Intranasal spray placebos may
not be comparable between
studies (eg, different volumes
and components)
No
Barnes et al
(2010)E4
To determine MCIDs for AR
Tx in clinical studies based
on TNSS
A validated,
quantitative anchor-
based approachE4
The GRCS was used as a direct
anchor, yielding MCID
thresholds of 0.23-0.28 points
for a TNSS scale of 0-12
Limitations:
 TNSS is not always reported in
range of 0-12; MCID needs to
be adapted to the scale used
Yes
Cohen’s d and
Hedge’s gE4,E5
A statistical calculation that
relates the change in an
outcome of interest to some
measure of its normal
variability, for example, the
sample SD of the TNSS at
BL
A validated,
quantitative,
distribution-based
approach
Cohen’s d
recommends any
change 0.2 times
the BL SD as
clinically
meaningful
Hedge’s g uses a
weighted average
of the BL SDs,
which is the same
approach to
approximate the SD
as the t-testE6
Easy to calculate when the
information regarding
variability is present
Limitations:
 Purely statistical assessment
with no link to a clinical
assessment
Yes
(continued)
APPENDIX E1. (Continued)
Method How used and/or developed Rating Comments
An appropriate global effect
measure for AR?
AHRQ
thresholdE7
(AHRQ, 2013)
To evaluate SAR treatments
based on TNSS
Arbitrary panel-based
recommendation of
30% change in
TNSS based on the
total scale range
(eg, 3.6 points
based on a 12-point
TNSS scale)
Used to assess meta-analyses of
single Tx and combinations of
Tx, but could not demonstrate
clinically meaningful beneﬁt
between different Tx, or even
between active Tx and placebo
control
Limitations:
 A subjective, nonvalidated
approach
 Attempted to apply a patient-
based perspective of MCID to
a population mean difference,
resulting in a gross
overestimation of the MCID
threshold
No
BL, Baseline; GRCS, global rating of change score; MCID, minimal clinically important difference; P, placebo; rTSS4, rhinitis total symptom score 4 (similar to TNSS); SAR,
seasonal allergic rhinitis; SD, standard deviation; Sx, symptoms; TNSS, total nasal symptom score; Tx, treatment(s).
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MCID THRESHOLD BASED ON BARNES ET ALE4
The distribution-based calculation described by Barnes et alE4
used to evaluate MCID thresholds for AR treatments was
Hedge’s g, a modiﬁcation of Cohen’s d. The latter is a commonly
used method to determine effect size by measuring the distance
between 2 means in relation to the baseline standard deviation of
the samples.E4,E6 For treatment effects in clinical trials in AR, the
calculation would be:E4,E6,E8-E10
d ¼ ðTreatment Mean 1 Treatment Mean 2ÞðBaseline Standard Deviation for the pooled samplesÞ
In general, Cohen’s d recommends as clinically meaningful
any treatment difference 0.2 times the baseline standard de-
viation, with effect sizes of 0.2, 0.5, and 0.8 standard deviations
suggested as small, moderate, and large effects, respectively.E4,E6
Hedge’s g uses a weighted average in the denominator of the
calculation, which may be preferable to Cohen’s d because it is
the same approach to approximate standard deviation as used in
the common t-test.E4,E6,E8-E10g ¼ ðTreatment Mean 1  Treatment Mean 2Þðweighted average of the Baseline Standard Deviations for both samplesÞAs for Cohen’s d, a treatment difference 0.2 times the
baseline standard deviation is considered clinically meaningful for
Hedge’s g.E4,E6,E8-E10
Applying the Hedge’s g calculation to the 9 pooled studies
described in their paper, Barnes et alE4 were able to deﬁne a
common estimate of the baseline standard deviation and multi-
plying that result by 0.2 (for a clinically meaningful change)
resulted in an MCID threshold of 0.59 for the TNSS on a12-point scale (1.18 units on a 24-point scale) for those
studies.E4,E9 It is important to recognize that because these cal-
culations are sample speciﬁc, the threshold determined (eg, 0.59
for the TNSS on a 12-point scale for the Barnes et al pooled
studiesE4) is also speciﬁc to that sample, so that it is better to
recalculate g in each study anew or to use a general estimate such
as the anchor-based approach.E4,E6,E8-E10
As an example, the reader is directed to the data from Study
MP4004 reported in thepaper byCarr et alE11 (seeTables 2 and3c).
The baseline standard deviation for the MP29-02 treatment group
was 3.3 with N ¼ 193; the baseline standard deviation for the
ﬂuticasone propionate (FP) group was 2.9 with N ¼ 189. There-
fore, the weighted average of the baseline standard deviations for
these 2 treatment groups is 3.10 using the following calculation:
Weighted average of BL SDs¼ð3:3 192þ 2:9 188Þð192þ 188Þ ¼3:10:
The treatment means for the 2 groups at 2 weeks were MP-
AzeFlu (aka MP29-02), 12.6; FP, 13.6. The difference in the
treatment group means (MP-AzeFlu  FP) ¼ 1.0, so the
calculation for Hedge’s g is as follows:Hedge’s g ¼ 1:0
3:1
¼ 0:32:
The absolute value (0.32) exceeds the MCID threshold for
Hedge’s g of 0.20. Therefore, the difference between the 2
treatment groups is considered to be at least minimally clinically
relevant, with MP-AzeFlu > FP.
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STRATEGY TO EXTEND THE LITERATURE
SEARCH FOR QUERIES 1, 2, AND 3
The dataset for analysis was extended to current (as of
September 8, 2015) using a modiﬁcation of the search strategy
described in the AHRQ reportE7 and the same electronic data-
bases—MEDLINE, EMBASE, and the Cochrane Library. The
following limits were applied: English, human subjects, dates
2012 (only studies published after July 18, 2012, considered) to
current (September 8, 2015).
The modiﬁcation involved adding the term human subjects as a
limit and simplifying some of the search terms for a more direct
approach appropriate to the scope of this article (eg, clinical trial
replaced placebo-controlled trial þ controlled trial þ randomized
controlled trial þ case cohort study þ observational trial þ cross-
sectional study). The search terms were applied as MeSH de-
scriptors, headers, and/or simple search terms according to the
structure of each database, and then combined as shown in
Appendix E3 Figure 1. Only search terms relevant to the 3
queries were included.
Any citations were reviewed for inclusion criteria as noted in
the text—seasonal allergic rhinitis, minimum of 2-week trial
duration, mild-to-moderate disease severity, symptoms scored by
TNSS, GRCS, or TSS4, and direct comparisons between
treatments as indicated by each query.Intranasal corƟcosteroid or nasal corƟcos
Beclomethasone or Beconase or Vancen
Budesonide or Rhinocort
Ciclesonide or Omnaris
Fluocinolone acetonide or flunisolide or 
FluƟcasone propionate or Flonase 
FluƟcasone furoate or Veramyst
Mometasone or Nasonex
Triamcinolone or AllerNaze or Nasocort
Histamine antagonists or anƟhistamine or H1-
antagonists
Non-sedaƟng anƟhistamine
CeƟrizine or Zyrtec or Alleroﬀ or Aller-tec
Loratadine or desloratadine or Clarinex or 
ClariƟn 
Terfenadine or fexofenadine or Allegra 
LevoceƟrizine or Xyzal
Brompheniramine
Carbinoxamine
Chlorpheniramine or dexchlorpheniramine
ClemasƟne
Diphenhydramine
Doxylamine
Triprolidine
Search 3 = 2753 records
Searches 3+2+1 = 9 records  (0)
Leukotriene Antagonists/
or Singulair
Search 4 = 1007
Searches 4+2+1 = 
QUERY 1: OAH+INCS vs. INCS QUERY 2: LTRA vs. INCS
RhiniƟs, Allergic, 
RhiniƟs, Allergic, 
RhiniƟs with seas
Hay fever or hayf
Clinical trial
Search 
Search 2 = 55
APPENDIX E3 Figure 1. Search strategy adapted from AHRQ Report.E7
followed by the number of records remaining after combining the appr
indicates how many citations were reviewed more closely for possibleOverall, for the individual search terms (with limits
applied), MEDLINE yielded 4714 records, EMBASE yielded
6177 records, and the Cochrane Library yielded 17 records.
The combined totals from each database and the number of
records speciﬁc to each query are shown in Appendix E2
Figure 1. After combining the terms for the individual queries,
only 3 citations were determined to be appropriate for review
under query 3: a poster presentationE12 and 2 long-term
studies of perennial and chronic rhinitis.E13,E14 None met
the inclusion criteria for the studies described by the AHRQ
report.E7APPENDIX E4: STUDY DESCRIPTIONS
Studies of treatments for seasonal allergic rhinitis (SAR)
that were used in the AHRQ evaluation of MCIDs are
included as described in the text. The TNSS presented is an
average of AM/PM scores reported by the subject unless
otherwise noted.
Patient inclusion criteria:
 A 2-year clinical history of SAR unless otherwise indicated;
 good health; no clinically signiﬁcant disease other than
SAR;
 positive skin prick test results in past year.teroid or intranasal steroid or nasal steroid 
ase
Nasalide or Nasarel
or Tri-nasal 
 or Montelukast
 CitaƟons
2 records (0)
Olopatadine or Patanase
AzelasƟne or Astelin or Astepro
AzelasƟne and FluƟcasone propionate or 
Dymista
Search 5 = 1240 CitaƟons
Searches 5 +1 = 11 records (3)
QUERY 3. INAH+INCS vs. INCS or vs. INAH
Perennial or PAR 
Seasonal or SAR 
onal or allergic 
ever
1 = 322 records
69 records
The number of records obtained is shown for each of 5 searches,
opriate searches for each of 3 queries. The number in parentheses
inclusion in the study table.
APPENDIX E4 TABLE 1. Study descriptions
Study
Study design and length of
active Tx
TNSS scale
maximum Tx (n) TNSS – SE/SD at BL
A lute change in
a
Query 1. Is there any clinical beneﬁt to adding an oral antihistamine to an intranasal corticosteroid (INCS)?
Anolik et al,
2008E15
R, DB, PG, PC; 15 d 12 MOM 200 mg þ LOR 10 mg (166)
MOM (166)
LOR (175)
P (165)
All QD
7.9  2.0
7.8  2.5
7.9  2.2
8.0  2.2
3
2
1
1
Barnes et al, 2006E5 R, DB, PC, crossover; 2
wk each phase
12 FP 200 mg þ LCET 5 mg (27)
FP þ P (27)
All QD
4.56  2.58 2
2
Ratner et al,
1998E16
MC, R, DD, DB, PG,
PC; 2 wk
400 (VAS) FP 200 mg þ LOR 10 mg (150)
FP (150)
LOR (150)
P (150)
All QD
304.9  4.7
304.9  4.6
313.3  4.0
302.4  4.2
1
1
1
1
Query 2. How does montelukast compare with an intranasal corticosteroid in terms of clinical beneﬁt?
Lu et al, 2009E17 Study 1*: R, DB, MC,
PG, PC; 2 wk
3 Study 1:
MON 10 mg QD (111)
LOR 10 mg QD (115)
MON þ LOR QD (174)
BDP 200 mg BID (172)
P (56)
Study 1:
2.06
2.11
2.04
2.03
2.04
Stu
0
0
0
0
0
Martin et al,
2006E18
R, DB, DD, PG, MC; 2 wk 400 (VAS) FP 200 mg (367)
MON 10 mg (369)
All QD
298.2  2.8
301.5  2.8
TN
1
9
Nathan et al,
2005E19
R, DB, PG, PC, MC; 4 wk 400 (VAS) FP 200 mg (291)
MON 10 mg (282)
P (290)
All QD
260.7  4.6
269.1  4.7
260.5  4.5
9
7
6
Ratner et al,
2003E20
R, DB, DD, PG, MC; 15 d 400 (VAS) FP 200 mg (353)
MON 10 mg (352)
All QD
296.2  2.7
298.9  2.7
1
9
Pullerits et al,
2002E21
R, DB, DD, PG, PC; 8 wk
(allergy season)
16 (used
scale of
0-4)
FP 200 mg (13)
MON 10 mg (16)
MON 10 mg þ LOR 10 mg (15)
P (18)
All QD
FP 200 mg (13)
TNSS day
1.5  1.4
1.9  2.1
1.9  1.5
2.4  2.3
TNSS night
0.9  1.2
TN
1.4
2.6
2.1
3.5
TN
0.7
6
8
8
.e4bsoTNSS – SE/SD (if
vailable) at 2 wk Comments
.0  2.0
.7  2.5
.9  2.2
.4  2.2
Values presented are means 
SD
.13
.02
Values presented are means  SE
where available
86.0  9.4
87.0  8.5
02.0  9.9
02.0  8.8
Physician-evaluated Sx scores
Values presented are
means  SE
dy 1:
.36
.53
.54
.70
.22
DT NSS ¼ average of 4 nasal Sx
scores, each on a 0-3 scale;
no SD or SE reported
SS day:
30.2 4.7
6.6  4.7
DT TNSS only
Values presented are
means  SE
9.1  5.8
3.0  1.3
0.7  5.8
Patients also had asthma and were
using FP and/or salmeterol
BID
DT TNSS for wk 1-2 only.
Values presented are
means  SE
30.3  4.7
4.0  4.7
Daytime TNSS only. Values
presented are means  SE
SS day:
 0.7
 0.5
 0.5
 0.4
SS night:
 0.6
<20 subjects per Tx arm.
Different type of comparison as
Tx began at start of 8-wk
pollen season so that Sx
stability and not change in
Sx was assessed
Values presented at BL are means
J
A
LLER
G
Y
C
LIN
IM
M
U
N
O
L
PR
A
C
T
JU
LY
/A
U
G
U
S
T
2
01
6
M
ELT
Z
ER
ET
A
L
MON 10 mg (16)
MON 10 mg þ LOR 10 mg (15)
P (18)
1.8  1.8
1.3  1.2
1.5  1.5
1.8  0.4
1.3  0.4
2.1  0.4
 SD; the changes are mean
TNSS averaged over wk 1-2
 SE
Query 3: Is there any clinical beneﬁt to adding an intranasal antihistamine to an INCS in a single device?
Hampel et al,
2010E22; Meltzer
et al, 2013E23
DB, PC, PG, R, MC; 2 wk 24 FP 100 mg (151)
AZE 274 mg (152)
MP29-02, aka MP-AzeFlu (153)
P (151)
All BID
18.3
18.1
18.8
18.7
3.84  4.76
3.25  4.16
5.31  5.08
2.2
Did not report SE or SD for BL
TNSS or for the P group
change
Values presented are means  SD
(where available)
Carr et al, 2012
Study MP4004E11,E24
DB, PC, PG, R, MC; 2 wk 24 FP 100 mg (189)
AZE 274 mg (194)
MP29-02, aka MP-AzeFlu (193)
P (200)
All BID
18.6  2.9
18.5  3.1
18.2  3.3
18.2  3.1
5.0  5.2
4.4  4.6
5.6  5.2
2.8  3.9
3 studies (MP4004, MP4002, and
MP4006) were included, as
shown
The sum of the AM and PM
TNSS scores was used
(scale 0-12 for both)
Values presented are means  SD
Carr et al, 2012
Study MP-4006E11
DB, PC, PG, R, MC; 2 wk 24 FP 100 mg (450)
AZE 274 mg (445)
MP29-02, aka MP-AzeFlu (448)
P (448)
All BID
19.4  2.4
19.5  2.5
19.4  2.4
19.5  2.4
5.1  4.7
4.5  4.8
5.6  5.2
3.2  4.3
Carr et al, 2012
Study MP-4002E11
DB, PC, PG, R, MC; 2 wk 24 FP 100 mg (207)
AZE 274 mg (208)
MP29-02, aka MP-AzeFlu (207)
P (209)
All BID
18.2  3.2
18.2  3.5
18.3  3.0
18.6  3.2
5.0  4.7
4.1  4.6
5.5  5.2
2.6  3.9
AM, Morning; AZE, azelastine; BID, twice daily; BDP, beclomethasone dipropionate; BL, baseline; DB, double blind; DD, double dummy; DT, daytime; FP, ﬂuticasone propionate; LCET, levocetirizine; LOR, loratadine; MC, multicenter;
MON, montelukast; MOM, mometasone furoate nasal spray; OAH, oral antihistamine; P, placebo; PC, placebo-controlled; PG, parallel group; PM, evening; QD, once daily; R, randomized; SAR, seasonal allergic rhinitis; SD, standard
deviation; SE, standard error; Sx, symptom(s); TNSS, total nasal symptoms score; Tx, treatment; VAS, visual analog scale; wk, week(s).
*The paper includes a second study (study 2) comparing montelukast and loratadine, with no INCS arm; the data from study 2, thus, were not appropriate for any of the queries.
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